Glenmark Pharma reports revenue growth of 22.5 per cent, EBITDA growth of 46.2 per cent YoY for Q1 FY 2023-24

Aug 12, 2023

Mumbai (Maharashtra) [India], August 12: Glenmark Pharmaceuticals Limited (Glenmark), an integrated, research-led, global pharmaceutical company, today announced its financial results for the first quarter...

Glenmark Pharma reports revenue growth of 26% and PAT growth of 21% YoY for Q1 FY 2021-22

Aug 14, 2021

Mumbai (Maharashtra) [India], August 14 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the first quarter...

Glenmark Pharma reports revenue growth of 6.6% and PAT growth of 10.1% YoY for Q2 FY 2021-22

Nov 13, 2021

Mumbai (Maharashtra) [India], November 13 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the second quarter...

Glenmark announces Q2 FY20-21 results

Nov 07, 2020

Mumbai (Maharashtra) [India], November 7 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited, a research-led global integrated pharmaceutical company, today announced its financial results for the second quarter...

Glenmark launches SUTIB (Sunitinib) - priced 96% lower than the innovator brand- Reduces the risk of kidney cancer progression by 58%

Feb 16, 2021

Mumbai (Maharashtra) [India], February 16 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched SUTIB, the generic version of Sunitinib oral capsules...

Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India

Oct 14, 2020

Mumbai (Maharashtra) [India], October 14 (ANI/PRNewswire): Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today launched NINDANIB (Nintedanib 100 and 150 mg capsules) for...